Abstract
Development of a novel RNA-based immune checkpoint inhibitor response signature (ICI-PRS) that avoids standard-of-care (SOC) prognostic signal for use in patients with urothelial cancer (UC).
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have